Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned

Celldex Therapeutics, Inc.

2022-Q3 EPS reported -$1.83 revenue$744,000

Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.
Revenue $0.4M in Q3, down from $0.2M in Q3 2021; R&D expenses rose to $21.6M on barzolvolimab trial and manufacturing.
Cash, cash equivalents and marketable securities $323.5M as of Sept 30, 2022; management says sufficient through 2025.
Phase 2 barzolvolimab studies in CSU, CIndU ongoing; 12-week data from Phase 1b CSU due Feb 2023; CIndU cohort data expected Dec 2022.
CDX-585 (ILT4 & PD-(L)1 bispecific) expected to enter clinic in 2023; CDX-527 (PD-L1 & CD27) discontinued due to evolving competitive landscape and internal hurdles.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celldex Therapeutics, Inc. reported financial results for third quarter of 2022.

Period: third quarter of 2022
Result: reported results

Exact text from the filing

On November 9, 2022, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.